Association between the CASC16 rs4784227 polymorphism and breast cancer risk and prognosis in a northeast Chinese Han population

Introduction

Breast cancer (BC) is the most common cause of cancer death in women and has become the most common form of cancer worldwide. Similarly, the estimated age-standardized incidence rate of BC is the highest among all cancers in China (Sung et al., 2021). The recurrence rate of patients with early breast cancer after surgery is relatively low (Weigel & Dowsett, 2010). According to information from the 2019 Chinese Society of Clinical Oncology (CSCO) Breast Cancer Annual Meeting, the 5-year survival rate of breast cancer in China was more than 80%. The increase in the cure rate of breast cancer in China depends on early detection, early diagnosis and early treatment. To improve the BC survival rate, early screening and early detection are critical and are designed primarily to identify those at high risk.

High-risk groups can be identified by risk factors such as female sex, early menarche, late menopause, increased estrogen exposure and excessive alcohol intake (Washbrook, 2006; Horn & Vatten, 2017; Dall & Britt, 2017; Jung et al., 2016). Additionally, gene detection is also feasible. Previous studies have shown that people who carry the breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2) variants are predisposed to breast cancer (Kurian et al., 2014). This is an indication that single nucleotide polymorphism (SNP) studies could help identify people with high susceptibility to breast cancer.

Cancer susceptibility candidate gene 16 (CASC16), is one of these genes that have been studied. CASC16 is an RNA gene that is located at chromosome 16q12.1 and is affiliated with the lncRNA class. One study showed that the CASC16 gene had higher expression in breast cancer cells than in normal cells (Han et al., 2016), and some loci of CASC16 have been demonstrated to be significantly associated with BC susceptibility  (Long et al., 2010; Zuo et al., 2020; Tajbakhsh et al., 2019; Lin et al., 2014). However, the association between this gene and other cancers has not yet been found. Rs4784227 is a locus of the CASC16 gene and previous studies showed that its MAF in Asian groups was in a range from 0.20 to 0.28 (https://www.ncbi.nlm.nih.gov/snp/rs4784227). It is well known that FOXA1 is involved in ESR1-mediated transcription, the regulation of cell apoptosis and cell cycle regulation. The place for rs4784227 on FOXA1 genomic for interaction is on the eighth position of the FKH motif recognized via FOXA1, thus, affinity DNA site for FOXA protein was enhanced for the T allele compared with the C allele in rs4784227, which suggested that the locus may affect a DNA binding sequence change on FOXA1 and modulate the chromatin affinity for FOXA1 (Tajbakhsh et al., 2019; Cowper-Sal Lari et al., 2012). However, whether the interaction between FOXA1 and CASC16 participates in the above functions and what will be caused by it are not clear. Current studies are limited to the relationship between this locus and BC susceptibility, and the functions of CASC16 are still unknown (Zuo et al., 2020).

Moreover, rs4784227 has been known to be linked to BC risk in previous studies conducted in Chinese populations, such as Shanghai, Tianjin, Nanjing and Taiwan (OR>1) (Long et al., 2010). However, these subject groups are mainly located in southern and coastal cities, and relatively little research has been done on inland areas. Investigations of this locus using a northeast Chinese population may verify whether the findings previously identified are generalizable to other populations. Data from a study published previously indicated that the rs4784227 SNP in CASC16 promotes lymph node metastasis in BC patients (Sun et al., 2020). In addition, stratified analysis using a genetic model indicated that rs4784227 was specific to progesterone receptor positivity (Deng et al., 2016). In addition, there have been no studies of the correlation between this locus and BC survival. Thus, in this article, we further explored the clinical features of SNP rs4784227 and its relationship with BC prognosis.

Subjects and Methods

Results

The relationship between the rs4784227 polymorphism of CASC16 and the prognosis of breast cancer

Among the 828 BC patients, 401 individuals were carrying the CC genotype, and the others were carriers of the CT or TT genotype in the dominant model. By using the log-rank test, we did not find that DFS and OS in BC cases were significantly associated with the rs4784227 polymorphism of CASC16 (DFS: P = 0.972, OS: P = 0.727) (Fig. 1).

All the above clinical characteristics of patients were included in the Cox model for multivariate analysis to examine the association between the genotypes of rs4784227 and DFS and OS of BC. The results suggested that the differences in DFS and OS among the different genotypes of the BC patients were not statistically significant (DFS: HR =1.037 (0.705–1.526) P = 0.855, OS: HR =1.224 (0.653–2.295) P = 0.529).

Discussion

To date, genome-wide association studies (GWAS) have identified numerous common variants associated with BC risk at multiple genetic loci (Deng et al., 2016). Therefore, conducting research on SNPs could help identify people with a high susceptibility to BC. As mentioned before, rs4784227 may affect the DNA binding sequence on FOXA1 and subsequently increase the FOXA1-binding affinity to the CASC16 gene promoter; FOXA1 plays an important role in the function of ER and growth of ER⁺ BC cells (Carroll et al., 2005; Kong et al., 2011). BC patients with ER and/or PR positivity accounted for approximately 75% of BC patients (Niemeier et al., 2010), and ER is an important indicator of treatment efficacy prediction and prognosis. Therefore, we wanted to know whether there was a connection between the rs4784227 polymorphism of CASC16 and susceptibility to BC, especially ER⁺BC. Thus, we selected the GWAS-identified SNP rs4784227 to investigate and verify its association with BC susceptibility and prognosis in the northeast Chinese Han population.

In our study, we found that the T allele was the minor allele of rs4784227, and the distribution of alleles and genotypes of SNP rs4784227 (C = 69.93%, T = 30.07%, CC =48.43%, CT = 43.00%, TT = 8.57%) was consistent with current research. The results indicated that those who carried the T allele had high BC susceptibility, which was in line with  Zuo et al. (2020), Tajbakhsh et al. (2019) and He et al. (2014). In our study, the best-fitting inheritance model of rs4784227 was the dominant model, and in this model, we found that the CC genotype of SNP rs4784227 provided a protective effect against BC, which was consistent with Zuo et al. (2020) and Tajbakhsh et al. (2019). However, Sun et al. (2020) did not find this association. The difference may be because the sample size in Sun’s research was relatively small (n_Zuo = 681, n_Tajbakhsh = 505, n_Sun = 503), so the results of the data analysis may be biased. The results of the northwest population in our study were the same as the populations in the southern and coastal cities in China, Japan and Europe. Therefore, racial and regional differences may not affect the association between this locus and BC susceptibility.

Regarding clinical features, He et al.’s (2014) study (n = 623) found that the T allele of rs4784227 exhibited significant associations with the status of ER, PR and HER2 in an additive model. In addition, Deng et al. (2016) indicated that SNP rs4784227 had a significant association with PR-positive tumor risk. Again, rs4784227 may affect the interactions between FOXA1 and CASC16, and FOXA1 may affect the status of ER. Thus, we investigated whether SNP rs4784227 could affect the expression of these three receptors, especially ER. Regrettably, in our study, this association could not be found in any of the three receptors. He et al.’s (2014) research suggested that rs4784227 increased BC risk in a dose-dependent manner, so homozygous carriers have higher susceptibility. Therefore, the difference mentioned above may be because the number of people who carried the TT genotype in our sample was small (8.57%), which was not enough to prove the relationship between this locus and the status of ER. Therefore, studies on larger sample sets and further functional identification of molecular mechanisms are needed to confirm the association mentioned above. Furthermore, the results indicated that the locus was associated with perineural invasion, menstrual status and histological grade of BC patients. Among them, the menstrual status results were consistent with  Lin et al. (2014). However, the same findings of perineural invasion and histological grade were not found in other studies. In addition,  Zuo et al. (2020) and Sun et al. (2020) found that there was a significant association between rs4784227 and lymph node metastasis status, but this conclusion was not reached in our study. We propose that this may be because the number of people who carried the TT genotype in our sample was small. Therefore, larger sample sizes and a meta-analysis are required to further verify this relationship.

Additionally, our study could not confirm that the rs4784227 polymorphism of CASC16 had an effect on the DFS and OS of BC patients. This may be because the sample time span was just 60 months and the disease-free survival of BC was long, so a longer follow-up period may be necessary.

Conclusions

Our findings suggest that the rs4784227 polymorphism of CASC16 may affect susceptibility to BC and was associated with perineural invasion, menstrual status and histological grade of BC patients. In addition, our results could not confirm that the rs4784227 polymorphism of CASC16 had an effect on the prognosis of breast cancer.

Supplemental Information